Table 3

Predictors of Major Adverse Events in the Elderly Group

Major Adverse EventsUnivariate AnalysisMultivariate Analysis
Yes (n = 40)No (n = 285)OR (95% CI)p ValueOR (95% CI)p Value
Age, yrs78.4 ± 2.878.1 ± 2.71.04 (0.92–1.17)0.557
Female20 (50%)117 (41%)1.44 (0.74–2.79)0.285
Body mass index, kg/m222.0 ± 3.323.3 ± 4.00.91 (0.82–0.99)0.048
Body weight, kg52.9 ± 10.858.4 ± 11.10.95 (0.92–0.99)0.0040.96 (0.93–0.99)0.010
Duration of AF, yrs3.7 ± 7.73.5 ± 4.81.01 (0.95–1.07)0.784
Paroxysmal AF30 (75%)208 (73%)1.11 (0.52–2.38)0.787
Antiplatelet drug use13 (33%)45 (16%)2.57 (1.23–5.35)0.0122.21 (1.04–4.67)0.039
DOAC use22 (55%)164 (58%)0.90 (0.46–1.76)0.761
Left atrial diameter, mm42.0 ± 6.540.0 ± 6.51.05 (0.99–1.10)0.069
Left ventricular ejection fraction, %62.0 ± 9.261.9 ± 9.71.00 (0.97–1.04)0.922
CHADS2 score2.1 ± 0.92.2 ± 0.90.85 (0.58–1.26)0.419
CHA2DS2-VASc score3.8 ± 1.03.7 ± 1.11.06 (0.79–1.43)0.681
HAS-BLED score2.1 ± 0.82.0 ± 0.81.11 (0.73–1.68)0.624
Impaired renal function (CrCl <50 ml/min)25 (63%)114 (40%)2.50 (1.26–4.95)0.009
First session for AF27 (68%)183 (64%)1.16 (0.57–2.34)0.684
Radiofrequency ablation35 (88%)240 (84%)1.31 (0.49–3.53)0.590

Values are mean ± SD or n (%).

CI = confidence interval; CrCl = creatinine clearance; DOAC = direct oral anticoagulant; OR = odds ratio; other abbreviations as in Table 1.

  • Variables included in the multivariate model using a forward stepwise method.